

Resource Summary Report

Generated by PRECISE-TBI on Sep 8, 2026

Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

RRID:SCR_025370

Type: Tool

Proper Citation

Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR_025370)

Resource Information

URL: <https://www.thermofisher.com/us/en/home/life-science/cell-analysis/cell-analysis-instruments/automated-cell-counters/resources/resources-countess-ii.html>

Proper Citation: Thermo Fisher: Invitrogen: Countess II Automated Cell Counter (RRID:SCR_025370)

Description: Fully automated cell counter and assay platform that uses optics and image analysis algorithms to analyze trypan blue-stained cells in suspension. Benchtop device that measures cell concentration and viability.

Synonyms: Countess II Automated Cell Counter

Resource Type: instrument resource

Keywords: cell counter, automated cell counter, assay platform, nalyze trypan blue-stained cells in suspension,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_025370.pdf

Resource Name: Thermo Fisher: Invitrogen: Countess II Automated Cell Counter

Resource ID: SCR_025370

Alternate IDs: Model_Number_Countess_II

Alternate URLs: https://assets.thermofisher.com/TFS-Assets/BID/manuals/MAN0014293_Countess_II_Automated_Cell_Counter_UG.pdf

Record Creation Time: 20240524T053223+0000

Ratings and Alerts

No rating or validation information has been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

No alerts have been found for Thermo Fisher: Invitrogen: Countess II Automated Cell Counter.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Renatino Canevarolo R, et al. (2025) Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma. Research square.

Yang W, et al. (2025) Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. Science advances, 11(29), eadw5228.

Piccoli M, et al. (2025) Direct Current Stimulation (DCS) Modulates Lipid Metabolism and Intercellular Vesicular Trafficking in SHSY-5Y Cell Line: Implications for Parkinson's Disease. Journal of neurochemistry, 169(2), e70014.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. Molecular cancer therapeutics, 24(9), 1415.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

Mattavelli G, et al. (2025) A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. Immunity.

Nelson AJ, et al. (2025) Lung-resident memory B cells maintain allergic IgE responses in the respiratory tract. Immunity, 58(4), 875.

MacMillan AC, et al. (2025) PRPS activity tunes redox homeostasis in Myc-driven lymphoma. Redox biology, 84, 103649.

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. *Cancer research*, 85(22), 4359.

Alam A, et al. (2022) Fungal ablation and transplantation of specific fungal species into PDAC tumor-bearing mice. *STAR protocols*, 3(3), 101644.

Governa P, et al. (2018) Effects of *Boswellia Serrata* Roxb. and *Curcuma longa* L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. *Pharmaceuticals* (Basel, Switzerland), 11(4).